Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 8, 2024
Emerging Company Profile
Avicenna: Using machine learning to skip the hit-to-lead phase
Seeded by DCVC Bio, Avicenna’s machine learning tech is designed to find a clinical candidate in a haystack of theoretical compounds
BioCentury | Jan 18, 2018
Emerging Company Profile
Computing brain entry
How 1st Biotherapeutics is applying computational tools to CNS drug discovery
BioCentury | Nov 10, 2017
Product R&D
Blueprint gets the GIST
How Blueprint’s BLU-285 targets mutant kinases resistant to front-line drugs
BioCentury | Apr 13, 2017
Targets & Mechanisms
Allosteric en-ABL-ement
Why Novartis is combining allosteric and catalytic site ABL inhibitors in CML
Items per page:
1 - 8 of 8